Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …

The assessment of bleeding and ischemic risk is a crucial step in establishing appropriate
composition and duration of dual antiplatelet therapy (DAPT) in patients with acute coronary …

Dual antiplatelet therapy (DAPT) is the gold standard after acute coronary syndromes (ACS)
or chronic coronary syndromes (CCS) undergoing percutaneous coronary intervention …

Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention has become the
standard of care, particularly in patients with acute coronary syndrome (ACS). Current …

Background Balancing the effects of dual antiplatelet therapy (DAPT) in the era of potent
P2Y12 inhibitors has become a cornerstone of acute coronary syndrome (ACS) …

Abstract Aims Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant
ischaemic benefit over clopidogrel after acute coronary syndrome (ACS). However, both …

Introduction The decision to shorten the duration of DAPT following PCI in patients with ACS
remains controversial because of the concern for increased ischemic events. Methods We …

Objectives Dual antiplatelet therapy (DAPT) with aspirin+ a P2Y12 inhibitor is recommended
for at least 12 months for patients with acute coronary syndrome (ACS), with shorter …

Objectives The aim of this study was to compare short dual antiplatelet therapy (DAPT) and
de-escalation in a network meta-analysis using standard DAPT as common comparator …

Inhibition of platelet function by means of dual antiplatelet therapy (DAPT) is the cornerstone
of treatment of acute coronary syndrome (ACS). While preventing ischemic recurrences …